- Home
- SGP vs APMD Comparison
SGP vs APMD Comparison
Compare SGP & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGP | APMD |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.4M | 895.5M |
| IPO Year | 2026 | 2026 |
Fundamental Metrics
Financial Performance| Metric | SGP | APMD |
|---|---|---|
| Price | $24.92 | $18.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $44.00 | ★ $50.33 |
| AVG Volume (30 Days) | 108.2K | ★ 469.3K |
| Earning Date | 11-10-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $136.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.06 | $17.38 |
| 52 Week High | $30.56 | $35.29 |
Technical Indicators
Market Signals| Indicator | SGP | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 35.00 |
| Support Level | $24.85 | N/A |
| Resistance Level | $26.29 | $29.88 |
| Average True Range (ATR) | 1.43 | 2.27 |
| MACD | -0.37 | -0.48 |
| Stochastic Oscillator | 29.19 | 13.04 |
Price Performance
Historical ComparisonAbout SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).